Proscaline Stats & Data
CCCOc1c(OC)cc(CCN)cc1OC.[H+]HYWLMSUAZVDUFW-UHFFFAOYSA-OReceptor Profile
Receptor Actions
History & Culture
Proscaline was first synthesized and investigated by Czech chemist Otakar Leminger in 1972. The compound was subsequently synthesized by David E. Nichols, who published his work in the Journal of Medicinal Chemistry in 1977. Around this period, Alexander Shulgin independently explored the substance, evaluating its effects at doses up to 60 milligrams and estimating its potency to be approximately five times greater than that of mescaline. Shulgin later documented his findings on proscaline in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), which served as the primary reference for the compound's subjective effects for many years. Despite this early documentation, proscaline remained largely obscure until it appeared for sale on the online research chemical market during the 2010s. The substance was first identified as a novel designer drug in Europe in 2013.
Toxicity
PsychonautWikiThe toxicity and long-term health effects of recreational proscaline use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. Anecdotal evidence from people who have tried proscaline within the psychedelic community suggests that there are no negative health effects attributed to trying this drug, but nothing can be completely guaranteed. It is strongly recommended that one use harm reduction practices when using this drug.
Effect Profile
Curated + 5 ReportsStrong visuals with moderate headspace and body load
Moderate euphoria with mild stimulation and anxiety/jitters, low focus
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 8 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 7 of 8
- Not Specified 1 of 8
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 5 experience reports (5 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 5 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 2
Adverse Effects 0
Real-World Dose Distribution
ErowidFrom 9 of 11 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.
Oral (n=9)
Form / Preparation
Most common forms and preparations, as a share of the 4 reports that give one
Too few reports for bars: these forms come from 4 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Capsule 2 of 4
- Powder / Crystals 2 of 4
Legal Status
| Country | Status | Notes |
|---|---|---|
| Germany | Controlled (NpSG) | Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, import with intent to distribute, administration to others, and trading are criminal offenses. Possession itself is prohibited but not subject to criminal penalty, though ordering may be prosecuted as incitement to market the substance. |
| Switzerland | Controlled (Verzeichnis E) | Classified as a controlled substance under Verzeichnis E, point 130, as a defined derivative of phenethylamine. Exemptions exist for scientific research and industrial applications. |
| United Kingdom | Class A | Controlled as a Class A substance under the Misuse of Drugs Act 1971 via the phenethylamine derivatives catch-all clause. Class A substances carry the most severe penalties under UK law. |
| United States | Unscheduled | Not specifically scheduled under the Controlled Substances Act. However, sale for human consumption could potentially trigger prosecution under the Federal Analogue Act due to structural similarity to mescaline, a Schedule I substance. |
References
Cited References
- Bluelight: Proscaline Discussion
- Erowid Experience Vault: Mind Candy (50mg)
- Erowid Experience Vault: Nothing Extreme (102mg)
- Erowid Experience Vault: Fully Psychedelic in the Most Subtle of Ways
- Erowid PiHKAL: Proscaline
- Erowid: Proscaline Experience Vault
- Halberstadt et al. (2020) - Comparison of the behavioral effects of mescaline analogs
- Isomer Design PiHKAL #140: Proscaline
- Nichols and Dyer (1977) - Journal of Medicinal Chemistry